Immunotherapy for glioblastoma: current state, challenges, and future perspectives
Cleveland Clinic Lerner College of Medicine · Northwestern University · +5 more institutions
Abstract
Glioblastoma (GBM) is an aggressive and lethal type of brain tumor in human adults. The standard of care offers minimal clinical benefit, and most GBM patients experience tumor recurrence after treatment. In recent years, significant advancements have been made in the development of novel immunotherapies or other therapeutic strategies that can overcome immunotherapy resistance in many advanced cancers. However, the benefit of immune-based treatments in GBM is limited because of the unique brain immune profiles, GBM cell heterogeneity, and immunosuppressive tumor microenvironment. In this review, we present a detailed overview of current immunotherapeutic strategies and discuss the challenges and potential…
Citation impact
- FWCI
- 91.70
- Percentile
- 100%
- References
- 289
Authors
5- YLYang LiuCorresponding
Cleveland Clinic Lerner College of Medicine
- ZFZhou Fei
Cleveland Clinic Lerner College of Medicine
- HAHeba Ali
Northwestern University, Neurological Surgery
- JDJustin D. Lathia
Cleveland Clinic, Cleveland Clinic Lerner College of Medicine, Case Comprehensive Cancer Center, Case Western Reserve University
- PCPeiwen Chen
Cleveland Clinic Lerner College of Medicine, University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Topics & keywords
- Immunotherapy
- Glioblastoma
- Medicine
- Immune system
- Tumor microenvironment
- Brain tumor
- Cancer research
- Oncology
- Good health and well-being